RxDoctor Payments Data

Stephen Becker, MD

Internal Medicine · Sunnyside, NYNPI 1366573396

Payments from drug & device makers

$2,086in general payments, 2019–2025

Across 86 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$617
  • Daiichi Sankyo Inc.$160
  • Amarin Pharma, Inc.$46
  • Novo Nordisk$35
  • Merck$33
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$2,07499%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca41$1,117
Lilly USA, LLC28$617
Daiichi Sankyo Inc.7$160
Amarin Pharma, Inc.2$46
Novo Nordisk2$35
Merck2$33
Pfizer1$22
Seqirus USA Inc1$20
Boehringer Ingelheim1$19
Althera Pharmaceuticals LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,086 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$189,692
Medicare patients
39
Services billed
2,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol28$34,714
MounjaroTirzepatide29$33,393
JardianceEmpagliflozin29$30,136
Ibandronate Sodium25$3,330
Valsartan65$1,044
Rosuvastatin Calcium79$1,014
Niacin ErNiacin11$462
Levetiracetam14$377
Atorvastatin Calcium27$319
Dutasteride13$294
Montelukast Sodium28$289
Levothyroxine Sodium33$286
Metoprolol Succinate23$260
Amlodipine Besylate44$180
Glimepiride20$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,117$34,71428 claims
Lilly USA, LLCMounjaro$617$33,39329 claims
Boehringer IngelheimJardiance$19$30,13629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Sunnyside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →